In high-risk outpatients, fluvoxamine reduced the likelihood of a composite outcome of hospitalization or need for extended emergency department evaluation.
Fluvoxamine — a selective serotonin reuptake inhibitor prescribed for various mental health disorders — has been proposed as a treatment for COVID-19, in part because of its putative anti-inflammatory effect. Observational data and a small randomized trial suggested benefit. Now, this drug has been tested in a placebo-controlled, adaptive platform trial enrolling high-risk outpatients with COVID-19 in Brazil.
Some 1500 participants with <7 days of symptoms and a known risk factor for severe COVID-19 were assigned 1:1 to receive fluvoxamine or placebo for 10 days. The primary outcome — a composite of observation in a COVID-19 emergency setting for >6 hours or transfer to a tertiary hospital — occurred in 11% of the fluvoxamine group and l6% o…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)